Industry | 2016.01.27
ONO PHARMACEUTICAL Selects Medidata to Power Clinical Trials Exploring Additional Cancer Indications for Immunotherapy Drug OPDIVO® (nivolumab)
NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, announced today that ONO PHARMACEUTICAL CO., LTD. (“ONO”) has expanded its adoption of the Medidata Clinical Cloud® to include all clinical trials testing the use of OPDIVO® (nivolumab) against a broad range of cancers. The Japan-based company will leverage Medidata’s industry-leading electronic data capture and management technology (Medidata Rave®) to
For more information, please visit
http://www.businesswire.com/news/home/20[...]Medidata-Power-Clinical-Trials
